Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands

Plain-language summary

This study aims to develop and validate a risk prediction model for the family members of people with ovarian cancer. It is open to people aged 18 and older who have a pathologically confirmed ovarian malignancy and carry a BRCA1/2 germline pathogenic mutation. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Peking University Third Hospital

Intervention

risk-reducing salpingo-oophorectomy (RRSO)

Start date

1/1/2016

Estimated completion

12/30/2035

Countries

China

Related genes

Locations

• Beijing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Pathologically diagnosed with ovarian malignant tumor.

  * Identified as carriers of BRCA1/2 germline pathogenic or likely pathogenic mutations through genetic testing, in accordance with the "Standards and Guidelines for the Interpretation of Sequence Variants" (2015 Edition) of the American College of Medical Genetics and Genomics (ACMG).

    * Age of 18 years or older. ④ Voluntary participation in this research and signing of the informed consent form.

Exclusion Criteria:

* ① Patients who refuse to provide necessary information.